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Abstract
Background: The presence of measles virus (MV) RNA in bowel tissue from children with autism spectrum disorders (ASD)
and gastrointestinal (GI) disturbances was reported in 1998. Subsequent investigations found no associations between MV
exposure and ASD but did not test for the presence of MV RNA in bowel or focus on children with ASD and GI disturbances.
Failure to replicate the original study design may contribute to continued public concern with respect to the safety of the
measles, mumps, and rubella (MMR) vaccine.
Methodology/Principal Findings: The objective of this case-control study was to determine whether children with GI
disturbances and autism are more likely than children with GI disturbances alone to have MV RNA and/or inflammation in
bowel tissues and if autism and/or GI episode onset relate temporally to receipt of MMR. The sample was an age-matched
group of US children undergoing clinically-indicated ileocolonoscopy. Ileal and cecal tissues from 25 children with autism
and GI disturbances and 13 children with GI disturbances alone (controls) were evaluated by real-time reverse transcription
(RT)-PCR for presence of MV RNA in three laboratories blinded to diagnosis, including one wherein the original findings
suggesting a link between MV and ASD were reported. The temporal order of onset of GI episodes and autism relative to
timing of MMR administration was examined. We found no differences between case and control groups in the presence of
MV RNA in ileum and cecum. Results were consistent across the three laboratory sites. GI symptom and autism onset were
unrelated to MMR timing. Eighty-eight percent of ASD cases had behavioral regression.
Conclusions/Significance: This study provides strong evidence against association of autism with persistent MV RNA in the
GI tract or MMR exposure. Autism with GI disturbances is associated with elevated rates of regression in language or other
skills and may represent an endophenotype distinct from other ASD.
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Introduction
Beginning in 1998, Wakefield and colleagues reported intestinal
abnormalities, including reactive lymphoid hyperplasia in ileum,
in children with autism and other developmental disturbances [1–
8]. These findings, combined with parent-reported associations of
timing of onset of behavioral abnormalities with MMR adminis-
tration, led to the hypothesis that MMR contributed to autism
pathogenesis [1]. Subsequent studies from this group reported MV
RNA in bowel biopsies and peripheral blood mononuclear cells
(PBMC) from children with ASD [9–12].
Over 20 epidemiologic studies reported no temporal relation-
ship between MMR and ASD [13–33], and three studies found no
MV RNA in PBMC of ASD children [34–36]; however, no
published studies from other research groups have addressed
whether MV RNA is present in bowel of ASD children with GI
disturbances. Here we report independent, blinded analysis of ileal
and cecal tissues from children with ASD and GI disturbances and
PLoS ONE | www.plosone.org 1 September 2008 | Volume 3 | Issue 9 | e3140children with GI disturbances but no neurological deficits for the
presence of MV RNA in three laboratories, including the one
where the original reports of an association between ASD and MV
were obtained.
Results
Forty-seven children were recruited. Six recruits did not
complete the study: 3 potential cases dropped out prior to
colonoscopy; 1 potential case and 2 potential controls completed
colonoscopy but had incomplete clinical assessments. No differ-
ences were found in age, sex, or case-control status between study
completers and non-completers. An additional 2 potential cases
were excluded for failure to meet diagnostic inclusion criteria
(below cutoffs for autistic disorder [AUT] on ADI-R); and 1 case
was excluded because no bowel biopsy material was available. The
final study population consisted of 25 cases (AUT/GI group) and
13 controls (GI control group) presenting consecutively for
ileocolonoscopy who received at least one dose of MMR and
completed all study procedures.
Age at biopsy was similar for cases and controls [median
(interquartile range, IQR), cases, 5.5 (3.0) years; controls, 5.1 (3.0)
years], as was the distribution of cases and controls across the three
age strata. Girls were older at biopsy than boys (P=0.01). There
were no significant differences between cases and controls in their
distribution by sex within the three age groups (Table 1).
The clinical indications for endoscopic/colonoscopic proce-
dures commonly noted in both AUT/GI and GI groups included
recurrent abdominal pain (RAP), gastroesophageal reflux, vomit-
ing, and food allergies. Although the more subjective factor of
RAP was frequently present in both cases (36%) and controls
(38%), it was rarely the sole rationale for GI examination in either
group (1 of 25 cases, or 4%; 2 of 13 controls, or 15%; P=0.27).
Median age at receipt of first MMR was similar for cases [15.3
(1.7) months] and controls [16.0 (4.9) months]. The majority of
study subjects were in the 3–5 year age stratum and below the age
recommended for second MMR (4–6 years [37]); expectedly, 80%
of cases and 69% of controls received only one MMR prior to the
study (P=0.36). Consistent with the older age of girls in the study,
there was a trend toward a higher proportion of girls than boys
receiving a second MMR (P=0.13). None of the children received
MV-containing vaccines other than MMR.
Clearance of MV depends on development of adaptive
immunity. As cell-associated MV RNA may be present transiently
Table 1. Subject characteristics.
SUBJECT CHARACTERISTIC AUT/GI CASES GI CONTROLS
SEX Male 23 (92) 9 (69)
n( % ) 3–5 years 15 7
6–7 years 6 1
8–10 years 2 1
Female 2 (8) 4 (31)
3–5 years 0 1
6–7 years 0 1
8–10 years 2 2
All subjects 25 (100) 13 (100)
ETHNICITY Caucasian 18 (72) 12 (92)
n (%) Asian 4 (16) 0 (0)
Hispanic 2 (8) 0 (0)
African-American 1 (4) 1 (8)
AGE STRATUM 3–5 years 15 (60) 8 (61)
n (%) 6–7 years 6 (24) 2 (15)
8–10 years 4 (16) 3 (23)
AGE AT BIOPSY All subjects 5.5 (3.0)
a 5.1 (3.0)
in years, median (IQR)
AGE AT FIRST MMR All subjects 15.3 (1.7)
b 16.0 (4.9)
in months, median (IQR) [RANGE] [12.2–22.8] [5.6–20.5]
TIME FROM LAST MMR TO BIOPSY All subjects 40.8 (26.7)
c 39.8 (21.1)
in months, median (IQR) [RANGE] [23.7–97.9] [3.5–64.5]
TOTAL NUMBER OF MMR VACCINES All subjects 20
d 31
% receiving 2 doses
TOTAL NUMBER OF ALL VACCINES All subjects 17 (4)* 20 (1)
median (IQR) [RANGE] [13–21] [15–22]
aMann-Whitney U, one-tailed, P=0.67.
bMann-Whitney U, one-tailed, P=0.15.
cMann-Whitney U, one-tailed, P=0.50.
dX
2, Fisher’s exact test, one-tailed, P=0.36.
*Mann-Whitney U, one-tailed, P=0.04.
doi:10.1371/journal.pone.0003140.t001
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biopsy was potentially important. Parental reports of timing of
MMR receipt 6 months or more prior to biopsy were in accord
with pediatric provider immunization charts for the final study
population with the exception of one control boy whose
immunization record revealed receipt of a second MMR 3.5
months prior to biopsy. This subject was retained in final analyses
after determining results to be the same both with and without
inclusion of his data. The median MMR-biopsy interval was
similar for cases [40.8 (26.7) months] and controls [39.8 (21.1)
months], and was not influenced by sex (Table 1). Older age at
biopsy was associated with a longer MMR-biopsy interval,
independent of case status (Spearman rank correlation,
Rho=0.65, p,0.0001).
Controls received a greater median number of all types of
vaccines than cases [20 (1) vaccines vs. cases, 17 (4); P=0.04,
Table 1). Total number of vaccines received was not related to age
or sex.
The study sample included two sibling pairs; three of these
children were controls (2 males, 1 female) and one was a case
(male). Data from sibling pairs were retained after determining
that patterns of results were unaltered by sibling pair exclusion.
Neuropsychiatric status
AUT diagnoses were confirmed for all cases. Absence of AUT,
other ASD, or other developmental disturbances was confirmed
for controls. For one control, ADI-R was incomplete; this subject
was retained after determining that CDI and clinical assessment
were consistent with typical development.
Median AUT onset age was 13.5 (7.0) months (Table 2). Cases
had a high rate of CPEA-defined behavioral regression (loss of
language and/or other skills following acquisition), 88%, com-
pared to published rates of 20–40% for the general ASD
population [27,40].
Real-time RT-PCR assays
Prior to examination of study samples, performance of the four
different primer sets (two for H gene, two for F gene) was
evaluated for the 12 cloned target regions using synthetic RNA
standards. A lower limit of detection of 50 RNA molecules per
reaction was confirmed for each primer set in all laboratories.
All laboratories correctly identified all positive controls using
pre-established criteria for positivity (positive results in at least two
of three wells with at least one of the primer pairs for F and one of
the primer pairs for H). All laboratories correctly identified all
negative controls.
Concordance across laboratories was achieved in the initial
round of real-time RT-PCR assays for all positive and negative
results with the exception of a single study sample, an ileal biopsy
from a control. An additional three samples, one ileal sample (from
a control) and two cecal samples (one case, one control) yielded
signal in at least one assay in one laboratory but did not meet
criteria for positivity. All four samples were retested as below to
resolve discrepancies.
As detailed above, only one sample met the pre-established
definition of discordance; in this instance, an ileal sample from a
control was positive with all four MV primer pairs in a single
laboratory. Neither of the other two laboratories reported positive
wells with any primer/probe combinations for this sample. The
amplification product from this reaction was sequenced and
determined to contain the engineered restriction site, confirming
that it represented the synthetic transcript control. This sample
was classified as negative. Aliquots of the three other samples that
had yielded signal in one assay in a single laboratory were shipped
to all three laboratory sites for retesting under new IDs. Two
negative and one positive control were included to ensure blinding
and monitor assay performance. Repeat testing of these three
discordant samples with the F or H gene sequence primer/probe
set responsible for the initial single positive finding failed to
reproduce positive results in any of the three laboratories on the
second round. In all three instances, results were negative on
second round testing, including the one laboratory initially
reporting positive results for a single primer pair.
MV RNA in bowel biopsies
Analyses in all three laboratories found two ileal biopsy samples
with MV F gene and H gene RNA: one from a boy in the AUT/
GI group, the other from a boy in the control group. Real-time
RT-PCR indicated a range of 2–7 molecules per PCR reaction,
corresponding to approximately 50–500 MV RNA molecules per
100 ng of total RNA extract (Table 3). Sequence analysis
confirmed that products of these samples were authentic. MV
RNA was not detected in cecum of these subjects, or in ileum or
cecum of any other subject. The presence of MV sequences was
not associated with an AUT diagnosis (cases, 4%, controls, 8%).
Both subjects with positive samples had reactive lymphoid
follicles (RLF). In the AUT/GI subject, RLF were present in both
small and large intestine; the control had RLF restricted to colon.
Endoscopy revealed inflammation in both subjects: the case had
nonspecific gastritis; the control had acute distal esophagitis. Other
cases and controls had RLF and/or inflammation in their upper
and lower GI tracts, but MV sequences were not detected in their
GI samples.
Timing of MMR, GI episodes and AUT
If MMR is causally related to either GI disturbances or AUT it
should precede their onset. Similarly, if GI disturbances contribute
Table 2. Onset of GI episodes and autism relative to MMR
administration.
Timing of event AUT/GI cases GI controls
(n=25) (n=13)
First MMR vaccine 15.3 (1.7)
a 16.0 (4.9)
age in months, median (IQR)
First episode of GI disturbance 12.0 (17.5)
b 2.0 (19.5)
age in months, median (IQR)
MMR before GI onset [n (%)] 12 (48)
c 3 (23)
MMR after GI onset [n (%)] 13 (52) 10 (77)
Autism onset 13.5 (7.0) Not applicable
age in months, median (IQR)
MMR before autism onset [n(%)] 13 (52) Not applicable
MMR after autism onset [n (%)] 12 (48) Not applicable
GI onset before autism [n (%)] 16 (64) Not applicable
GI onset after autism [n (%)] 9 (36) Not applicable
MMR before GI onset [n (%)] 5 (20) Not applicable
,AND.
GI onset before autism [n (%)]
Key: MMR, Measles-Mumps-Rubella vaccine.
aMann-Whitney U, one-tailed, p=0.15.
bMann-Whitney U, one-tailed, p=0.29.
cX
2, Fisher’s exact test, one-tailed, p=0.13.
doi:10.1371/journal.pone.0003140.t002
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temporal relationships in the following manner: subjects with
MMR administration and GI onset in the same month were
considered to have MMR administration before the onset of GI
episodes; subjects with GI episode and AUT onset within the same
month were considered to have GI onset before AUT onset; and
subjects with MMR and AUT onset within the same month were
considered to have MMR onset before the onset of AUT.
There were no significant differences in the proportion of cases
and controls with MMR before onset of GI episodes: 12 of 25
cases (48%) received MMR before GI episodes began as compared
with 3 of 13 controls (23%; P=0.13; Table 2). To examine whether
the MMR-GI onset interval differed for cases and controls,
survival analysis was pursued, using only those children with onset
of GI episodes after MMR administration. Kaplan-Meier analysis
showed no differences between cases and controls in latency from
MMR to initial GI disturbances (Mantel-Cox logrank test).
To determine whether our data supported the hypothesis that
GI pathology contributes to ASD pathogenesis, we examined the
temporal relationship between MMR immunization, first GI
episode, and AUT onset. If the putative relationship of MMR to
GI pathology and AUT is valid, MMR must precede GI
dysfunction and AUT, and GI dysfunction must precede AUT.
If GI dysfunction contributes to AUT independent of MMR, it is
necessary only that GI dysfunction precede development of AUT.
X
2 analyses indicated no role for MMR in either the pathogenesis
of AUT or GI dysfunction (Table 4). Only 5 of 25 subjects (20%)
had received MMR before the onset of GI complaints and had
also had onset of GI episodes before the onset of AUT (P=0.03).
Cases first receiving MMR prior to onset of GI complaints were
older at index GI episodes [21.0 (22.0) months] than cases
receiving their first MMR after GI episodes already began [1.0
(12.0) months; p,0.0001; Table 5]. Conversely, cases with GI
episodes preceding AUT onset had much earlier onset of GI
problems than cases with initiation of GI episodes after onset of
AUT [2.5 (13.0) vs. 30.0 (23.3) months, respectively; P=0.001].
Discussion
We found no differences between AUT/GI and GI control
groups in detection of MV sequences in RNA extracted from ileal
or cecal biopsy specimens. Real-time RT-PCR assays with
molecular controls engineered to allow differentiation of products
arising from synthetic vs. bone fide MV RNA produced consistent
results across three laboratories, with each laboratory site
reporting less than 10 cDNA copies of MV F and H gene in
ileal biopsies from one child with autism and one child without
neurological disorder.
Table 4. Number and frequency of AUT/GI subjects receiving
MMR before or after GI onset and with index GI episode
before or after ASD.
ORDER OF EVENTS CASES
(n=25)
GI before ASD GI after ASD
n (%) n (%)
MMR before GI 5 (31)
{ 7 (78)
MMR after GI 11 (69) 2 (22)
{X
2, Fisher’s exact test, one-tailed, p=0.03.
doi:10.1371/journal.pone.0003140.t004
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of 75% of ASD vs. 6% of control children [10,41]. Discrepancies
are unlikely to represent differences in experimental technique
because similar primer and probe sequences, cycling conditions
and instruments were employed in this and earlier reports;
furthermore, one of the three laboratories participating in this
study performed the assays described in earlier reports. Other
factors to consider include differences in patient age, sex, origin
(Europe vs. North America), GI disease, recency of MMR vaccine
administration at time of biopsy, and methods for confirming
neuropsychiatric status in cases and controls. Participation in the
current study required confirmation in cases of the presence of an
AUT diagnosis and exclusion in controls of AUT or other
developmental disturbances.
MV in MMR has been proposed to induce GI inflammation,
increasing permeability to neuroactive chemicals that promote
developmental neuropathology [42–43]. If this model is correct,
MMR immunization should precede GI complaints, and both
MMR and GI complaints should precede onset of ASD. We found
the age at the time of exposure to MMR relative to onset of GI
problems in cases and controls and the temporal order of MMR
administration, GI episodes, and AUT onset in cases to be
inconsistent with a causal role for MMR vaccine as a trigger or
exacerbator of either GI disturbances or autism.
ASDs comprise a wide range of endophenotypes that may
represent different routes to pathogenesis. The work reported here
eliminates the remaining support for the hypothesis that ASD with
GI complaints is related to MMR exposure. We found no
relationship between the timing of MMR and the onset of either
GI complaints or autism. We also could not confirm previous work
linking the presence of MV RNA in GI tract to ASD with GI
complaints. The origin, nature, and frequency of GI disturbances
within the larger ASD population remain unclear; focused
research strategies are required to define these endophenotypes
and determine their significance for causal hypotheses.
Materials and Methods
Human subjects
Families of potential subjects were invited to participate if
ileocolonoscopy with biopsy was specifically indicated as part of
clinical care. Invited children were scheduled for upper and/or
lower endoscopic procedures based on clinical imperative. Routine
informed consent for clinical procedures was obtained by the
gastroenterologist. Informed consent procedures detailed addi-
tional research procedures to be performed, and specific written
permission was provided by consenting parents and guardians and
children capable of providing assent (7 years or older). Study
procedures were approved by the Institutional Review Boards of
Partners/MGH, CU Medical Center, and the CDC and by the
Ethics Committee of Coombe Women’s Hospital prior to study
initiation.
Subjects
Children between 3 and 10 years of age were serially and
prospectively recruited from the Pediatric Gastroenterology and
Nutrition and LADDERS Clinics (MGH) in the years 2003 to
2005 into two groups if they had clinically significant GI
disturbances requiring ileocolonoscopic examination and either:
1) presence of Autistic Disorder (AUT; suspected or assigned)
(AUT/GI cases), or 2) absence of known or suspected develop-
mental disturbances (GI controls). Potential controls were
frequency-matched to potential AUT/GI cases within three age
strata: 3–5, 6–7, or 8–10 years. Eligible children received at least
one prior immunization containing MV vaccine strain. Children
reported by parents to have received MV immunization within 6
months of planned biopsy were excluded.
Clinical procedures
Neuropsychiatric status was established for all subjects by child
neurologists, psychiatrists or developmental pediatricians (LAD-
DERS) using Diagnostic and Statistical Manual-Fourth Edition,
Text Revision (DSM-IV-TR [44]) diagnostic criteria. Cases failing
to meet full DSM-IV-TR criteria for AUT (299.00 code) were
excluded from further analysis, including subjects with diagnoses
of any DSM-IV-TR pervasive developmental disorder (PDD)
other than AUT (PDD-Not Otherwise Specified, Asperger’s
Disorder, Childhood Disintegrative Disorder, Rett’s Disorder) or
genetic syndromes associated with ASD features (Fragile X,
tuberous sclerosis, neurofibromatosis, trisomy 21).
Data were obtained from parents by trained clinical raters using
standardized data collection forms. Pediatrician records were
acquired to confirm parent-reported dates, types, brands, and lot
Table 5. Ages of AUT/GI subjects receiving MMR before or after GI onset and with index GI episode before or after ASD.
ORDER OF EVENTS AGE AT EVENT
in months, median (IQR)
First MMR First GI episode ASD onset GI biopsy
MMR before GI (n=12) 15.1 (3.2) 21.0 (22.0)** 16.0 (5.5) 58.2 (32.1)
MMR after GI (n=13) 15.8 (0.6) 1.0 (12.0) 12.0 (9.5) 74.8 (37.3)
GI before ASD (n=16) 15.3 (1.0) 2.5 (13.0)* 13.5 (4.5) 64.5 (35.2)
GI after ASD (n=9) 15.3 (4.3) 30.0 (23.3) 12.0 (13.0) 71.3 (34.8)
MMR before GI 15.0 (4.7) 15.0 (6.5) 16.0 (6.0) 52.2 (29.4)
,AND. GI before ASD (n=5)
NOT MMR before GI 15.3 (0.9) 12.0 (22.0) 12.0 (10.5) 68.4 (33.1)
,AND. GI before ASD (n=20)
All AUT/GI cases (n=25) 15.3 (1.7) 12.0 (17.5) 13.5 (7.0) 65.6 (35.7)
**Mann-Whitney U, one-tailed, p,0.0001.
*Mann-Whitney U, one-tailed, p=0.001.
doi:10.1371/journal.pone.0003140.t005
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Autism Diagnostic Interview-Revised (ADI-R [45]) and Shortened
CPEA Regression Interview, modeled on the MacArthur
Communicative Development Inventory (CDI) (courtesy of
Catherine Lord) [27,46–49]. Certified raters administered the
ADI-R to caregivers of cases to confirm DSM-IV-TR AUT
diagnoses using established cutoffs [49]. Controls were evaluated
in the same manner as cases to exclude subjects with ASD or other
developmental disturbances.
Regression status (loss of language and/or other skills) was
established according to well-validated CPEA algorithms [27,48–
49]. All diagnostic information (ADI-R, CDI, clinician diagnosis)
was reviewed by a single pediatric neurologist to ensure
consistency.
Blinding
A randomized list of linked clinical and laboratory ID codes was
prepared by the Biostatistics Core (CU) prior to study initiation and
provided to MGH research assistants. The MGH clinical coordina-
tor acquired, recorded and transmitted clinical data on case report
forms identified only by clinical ID. To maintain the blind, patient
samples were labeled at MGH with only the linked laboratory ID
codes and shipped to the Laboratory Core (CU). Samples were
maintained under laboratory codes for all assays at all three sites,
including any repeat assays required to address inter-laboratory
discordance. Linkage of clinical and laboratory ID codes remained
with the Biostatistics group until inter-laboratory discordance was
resolved and data qualitycontrol procedureswere complete;a linked
dataset was then prepared and final data analysis ensued.
Sample acquisition
Biopsy material was obtained from terminal ileum and cecum
under direct supervision of the team gastroenterologist. For analyses
of MV RNA, four random samples were taken from superficial
mucosae of ileum and cecum. Additional specimens were acquired
at sites indicative of inflammatory GI lesions, if present. All samples
intended for RNA analysis were frozen immediately in coded tubes
in liquid nitrogen and stored at 270uC until shipment to CU on dry
ice. Frozen biopsy specimens were stored in a dedicated 270uC
freezer until RNA extraction to avoid inadvertent contamination. A
portion of each clinical pathology sample also was retained under
blind for histopathologic analysis.
Preparation of RNA
Total RNA from bowel biopsies was obtained by acid
guanidinium thiocyanate-phenol-chloroform extraction (TRI-Re-
agent, Molecular Research Center) at CU. Aliquots of RNA were
prepared to ensure sufficient material for primary analysis at each
of the three laboratory sites and for repeated analyses in the event
results among sites were discordant. One 16 mg aliquot of RNA
was created for each region (ileum, cecum, lesion) and sent to the
three analytical laboratories for real-time RT-PCR detection of
MV F and H gene sequences using two primer/probe sets each, as
well as a control gene. To reduce the possibility that prior results
might influence interpretation of repeat laboratory tests, additional
aliquots of total RNA were coded with different laboratory IDs
and stored at 270uC.
Assay development
Three laboratory sites participated in MV RNA analyses: 1)
Coombe Women’s Hospital, Trinity College; 2) Center for
Infection and Immunity, CU, New York; 3) Measles, Mumps,
Rubella, and Herpesvirus Laboratory Branch, CDC, Atlanta.
Real-time RT-PCR assays employed four primer/probe sets:
the sets originally described by Uhlmann et al. [10] for targeting F
(fusion protein) and H (hemagglutinin protein) gene regions, and
newly selected primer/probe sets targeting different regions in F
and H gene sequences.
Synthetic MV transcripts were used as positive controls. These
transcripts contained engineered mutations to allow distinction
from bona fide MV sequences. A common cellular gene (b-actin)
was used as a control for integrity of RNA template. Negative
controls included reactions where water or normal human
placental RNA was substituted for clinical sample RNA.
Additional details on primer pair design, positive and negative
controls, and real-time RT-PCR assay calibration and procedures
are provided in Appendix S1.
Criteria for concordance
A positive finding in a single laboratory for each individual
sample was defined as any result above the detection threshold
(valuesabove baselineand belowaCtof45)intwoofthree triplicate
reaction wells in a 96-well plate, for any single set of F or H primers,
within that laboratory. The Biostatistics Core assessed coded data
fromeachlaboratoryforpositiveresultsbyGIregion(ileum,cecum,
lesion)and byprimerpair, aswell as forconcordance of positive and
negative findings across laboratories. All positive findings for a
specific sample (RNA from one GI region, from a single subject)
were first evaluated within each laboratory to determine whether
both F gene and H gene MV sequences were represented (detection
of RNA on the basis of two or more wells positive out of three, with
either or both of the two primer/probe combinations for F and H
gene regions). Concordance with respect to positive findings for a
specific primer pair and GI regionfor an individual subject was next
examined across laboratories; findings consistent in two or more
laboratories for any primer pair/GI region were defined as
concordant results. Samples for which at least two laboratories
reported a positive finding with at least one F gene primer set and at
least one H gene primer set were defined as positive for the presence
of MV sequences (Appendix S2). Discordance across laboratories was
defined as the presence of positive findings with at least one F gene
primer set and at least one H gene primer set in a single laboratory.
Data reporting and analysis
Assay results were reported under laboratory ID directly to the
Biostatistics Core via a secure website. Prior to breaking the sample
code,theBiostatistics Corereviewed consistencyofresults acrossthe
three sites for each individual sample. Concordance across
laboratories was required for every positive and negative control
as well as for each study sample. In instances where discordant
results were noted across sites for any sample (including positive and
negative controls), the Biostatistics Core notified the coordinating
laboratory that additional aliquots of that sample were to be sent to
each of the analytical laboratory sites for repeat assays. This process
continued until any such inconsistencies were resolved. Products
from positivereaction wellsweresequencedto ensure theabsence of
engineered restriction sites and identify bona fide positives.
Statistics
Group comparisons were conducted using nonparametric tests
(Mann-Whitney U test; nominal a=0.05) for continuous data
deviating from normal distributions, and chi-square (X
2) analyses
for nominal data (Fisher’s Exact Test to determine significance).
One-tailed tests for significance were pursued unless otherwise
indicated, given the study objectives of determining whether MV
sequences were more likely to be found in biopsy tissues of cases
than controls, as previously reported by Wakefield and colleagues
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Meier survival analysis was employed to examine whether the time
between MMR exposure and onset of GI episodes differed for
cases and controls, excluding subjects with index GI episodes
occurring before MMR. A Mantel-Cox logrank test was used to
compare survival curves after determining that assumptions of the
test were met (e.g., independent, random samples; lack of
correlation among covariates). Spearman rank correlation was
used to evaluate whether older age at biopsy was associated with
longer MMR biopsy intervals, independent of case status.
StatView for Windows, version 5.0.1 (SAS Institute) and SPSS
for Windows, version 15.0 (SPSS, Inc.) statistical software were
employed for these analyses.
Supporting Information
Appendix S1 Appendix S1 includes text, fig S1A, fig S1B, and
table S1, with supplemental information regarding molecular
methods and primer design
Found at: doi:10.1371/journal.pone.0003140.s001 (0.19 MB
DOC)
Appendix S2 Figure S2, study criteria and methods for resolving
intra- and inter-laboratory disconcordance
Found at: doi:10.1371/journal.pone.0003140.s002 (0.11 MB
DOC)
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